Cited by 51Pancreatic function and diabetesDiabetes and associated disordersDiabetes Management and Research

Hope vs hype: where are we in type 1 diabetes?

Open access
Skyler, Jay S.·2018·Diabetologia

Abstract

Much progress has been made in type 1 diabetes research. Biological replacement of islet function has been achieved with pancreas transplantation and with islet transplantation. In the future, human embryonic stem cells and/or induced pluripotent stem cells may offer a potentially unlimited source of cells for islet replacement. Another potential strategy is to induce robust beta cell replication so that regeneration of islets can be achieved. Immune interventions are being studied with the hope of arresting the type 1 diabetes disease process to either prevent the disease or help preserve beta cell function. Mechanical replacement of islet cell function involves the use of glucose sensor-controlled insulin infusion systems. As all of these avenues are pursued, headlines often overstate the case, thus hyping any given advance, which provides enormous hope for patients and families seeking a cure for type 1 diabetes. Often, however, it is an animal study or a pilot trial that is being described. The reality is that translation to successful trials in human beings may not be readily achievable. This article discusses both the hype and the hopes in type 1 diabetes research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-017-4530-x

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Survival and patient health have improved considerably, particularly in the past 25 years.

    “Although survival and patient health have improved considerably, particularly in the past 25 years, a cure for type 1 diabetes remains elusive.1,2”

    From Type 1 diabetes (2018) · cites this paper as [2]

    The Pancreas transplantation section (page unavailable) reports better 10-year survival for patients receiving a combined pancreas–kidney transplant than for those receiving a kidney transplant alone, and describes improving transplant outcomes. It does not establish that survival and health improved considerably for people with type 1 diabetes generally, particularly over the past 25 years. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • A cure for type 1 diabetes remains elusive.

    “a cure for type 1 diabetes remains elusive.1,2”

    From Type 1 diabetes (2018) · cites this paper as [2]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

Research works printed but not linked: 2

  1. Skyler JS (1984) Diabetes in 2021 -One hundred years after insu- lin. In: Baba S, Gould M, Zimmet P (eds) Diabetes -recent knowl- edge on aetiology, complications and treatment. Academic Press, Sydney, pp 237-252
  2. JDRF and ViaCyte announce support for development of pec-direct cell replacement therapy for type 1 diabetes. Press Release 22 May 2017. http://viacyte.com/press-releases/jdrf-and-viacyte- announce-support-for-development-of-pec-direct-cell-replacement- therapy-for-type-1-diabetes/. Accessed 2 October 2017

Cited by

Sorted by citations

Authors
Skyler, J. S.
Affiliations
University of Miami (US)
Corresponding author
Skyler, Jay S.
Venue
Diabetologia
Published
2017-12-23
Volume
61
Issue
3
Pages
509-516
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2776088746
Cited by
51
References
68
Citations by year
2026: 1 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 11 · 2021: 9 · 2020: 4 · 2019: 8 · 2018: 8
FWCI
1.16
Type
journal article
Language
en
Open access
Locations
  • Diabetologia (publishedVersion)
  • PubMed (publishedVersion)
Funders
Diabetes Research Institute Foundation (n/a)
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 1 diabetes, islet transplantation, pancreas transplantation, beta cell regeneration, human embryonic stem cells, induced pluripotent stem cells, immune intervention, research hype, translational research, disease prevention
MeSH terms
Animals, Diabetes Mellitus, Type 1, Humans, Insulin Infusion Systems, Islets of Langerhans Transplantation, Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review